What is the appropriate immediate management for a 32‑year‑old Filipino woman presenting with sudden hypertension, proteinuria, anemia, and diffuse isolated retinal vascular sheathing suggestive of lupus nephritis with retinal vasculitis?

Immediate Management of Suspected Lupus Nephritis with Retinal Vasculitis

This patient requires urgent initiation of high-dose glucocorticoids combined with a second immunosuppressive agent (mycophenolate mofetil or cyclophosphamide), plus hydroxychloroquine, while simultaneously arranging urgent kidney biopsy to confirm lupus nephritis class and guide definitive therapy. 1, 2, 3

Clinical Context and Urgency

The constellation of sudden hypertension, proteinuria, anemia, and diffuse retinal vascular sheathing in a young Filipino woman strongly suggests active systemic lupus erythematosus (SLE) with lupus nephritis and retinal vasculitis. Retinal vasculitis as a presenting manifestation of SLE is rare but well-documented 4, 5, and when combined with renal involvement, indicates severe multisystem disease requiring aggressive immediate treatment to prevent irreversible organ damage and preserve both vision and kidney function.

Immediate Treatment Protocol (Before Biopsy Results)

1. Glucocorticoid Therapy

• Initiate IV methylprednisolone pulse therapy: 500-1000 mg daily for 3 consecutive days 1, 2, 3
• Follow with oral prednisone: 0.5-1 mg/kg/day (maximum 60 mg/day), with rapid taper planned 1, 2
• The pulse dosing allows for more rapid oral taper and reduced cumulative glucocorticoid exposure 6

2. Second Immunosuppressive Agent (Start Immediately)

Choose one of the following based on local availability and patient factors:

• Mycophenolate mofetil (MMF): 2-3 g/day in divided doses (preferred first-line option) 1, 2, 3

  • Better tolerated than cyclophosphamide
  • Equally effective for most lupus nephritis classes
  • Contraindicated in pregnancy

• Cyclophosphamide: IV 500-1000 mg/m² monthly for 6 doses (alternative first-line) 1, 2

  • Consider if adherence concerns exist (IV administration ensures compliance) 1
  • May be preferred for severe, rapidly progressive disease
  • Higher toxicity profile (gonadal toxicity, hemorrhagic cystitis)

3. Hydroxychloroquine

• Start 200-400 mg daily (5 mg/kg/day, maximum 400 mg) 1, 2
• Essential for all SLE patients
• Reduces flares and improves long-term outcomes
• Requires baseline ophthalmologic examination given existing retinal disease

4. Adjunctive Therapies (Start Immediately)

Blood Pressure Control:

• Target BP <130/80 mmHg 1
• ACE inhibitor or ARB for renin-angiotensin system blockade 1
• Provides both BP control and antiproteinuric effect

Supportive Care:

• Monitor for and treat complications of nephrotic-range proteinuria (thrombosis, dyslipidemia, edema) 1
• Consider prophylactic anticoagulation if nephrotic syndrome develops
• Avoid nephrotoxins 6

Diagnostic Workup (Urgent, Within 24-48 Hours)

Essential Laboratory Tests

• Serologic confirmation: ANA, anti-dsDNA, complement levels (C3, C4), complete blood count, comprehensive metabolic panel
• Quantify proteinuria: 24-hour urine protein or spot urine protein-to-creatinine ratio
• Assess kidney function: Serum creatinine, estimated GFR
• Antiphospholipid antibodies: Given retinal vascular occlusion risk 5
• Urinalysis with microscopy: Look for active sediment (RBC casts, dysmorphic RBCs)

Kidney Biopsy (Arrange Urgently)

• Essential for definitive diagnosis and classification 1, 2, 3
• Determines lupus nephritis class (III, IV, V, or mixed)
• Guides intensity and duration of therapy
• Do not delay treatment while awaiting biopsy - start immunosuppression immediately 1, 2
• Even patients with proteinuria <500 mg/g can have significant lupus nephritis (85% in one series) 7, so biopsy is critical

Ophthalmologic Evaluation

• Urgent ophthalmology consultation for formal assessment of retinal vasculitis 4, 5
• Fluorescein angiography to document extent of vascular involvement
• Monitor for neovascularization requiring panretinal photocoagulation 5

Multitarget Therapy Approach

The 2024 KDIGO guidelines emphasize that lupus nephritis therapy is continuous, not divided into discrete "induction" and "maintenance" phases 1, 6, 2. The goal is:

• Rapid achievement of complete remission: Proteinuria <0.5 g/g (50 mg/mmol) with stable kidney function within 6-12 months 1
• Continue dual immunosuppression for 3-5 years after achieving complete renal response 2
• Maintain low-dose prednisone (≤5 mg/day) during maintenance 3

Consider Adding Biologic Therapy

For patients at high risk of progression (which this patient appears to be, given multisystem involvement):

• Belimumab: Can be added to standard therapy from the outset 1, 6
• Voclosporin (calcineurin inhibitor): Shown to achieve faster proteinuria reduction (median 3.6 months to <0.5 g/g) 1, 6
• These agents may be considered as "add-on" therapy to glucocorticoids plus MMF or cyclophosphamide 1, 2, 3

Monitoring and Response Assessment

Early Monitoring (First 3 Months)

• Check treatment adherence regularly - nonadherence rates exceed 60% in SLE 1
• Monitor proteinuria monthly
• Assess kidney function (creatinine, eGFR) every 2-4 weeks
• Expect to see improvement by 2-3 months 1

Definition of Treatment Response

• Complete response: Proteinuria <0.5 g/g, stable/improved kidney function within 6-12 months 1
• Partial response: ≥50% reduction in proteinuria to <3 g/g, stable kidney function within 6-12 months 1
• No response: Failure to achieve partial or complete response by 6-12 months 1

Management of Refractory Disease

If inadequate response by 3-4 months 1:

1. Verify adherence - consider switching oral MMF to IV cyclophosphamide if nonadherence suspected 1
2. Check drug levels if on mycophenolic acid 1
3. Consider repeat biopsy to assess for chronicity or alternative diagnosis (e.g., thrombotic microangiopathy) 1
4. Switch or add therapy:
   • Add rituximab (response rates 50-80% in refractory cases) 1
   • Consider obinutuzumab or other biologics 1
   • Extended cyclophosphamide course 1

Critical Pitfalls to Avoid

1. Do not wait for biopsy results to start treatment - organ damage is time-dependent
2. Do not use glucocorticoids alone - dual/triple immunosuppression is standard 1, 2, 3
3. Do not undertaper glucocorticoids - maintain at ≤5 mg/day during maintenance, not zero 3
4. Do not stop maintenance therapy early - continue for minimum 3 years to prevent flares 2, 3
5. Do not ignore retinal vasculitis - requires ophthalmologic monitoring and may need additional interventions 4, 5
6. Do not assume low proteinuria excludes significant lupus nephritis - biopsy may still show Class III-V disease 7

Special Considerations for Filipino Patients

• Asian populations may respond well to triple immunosuppression (glucocorticoids + tacrolimus + low-dose MMF), with complete remission rates of 33% vs 8% with cyclophosphamide-based regimens 1
• The APLAR 2024 consensus specifically addresses management in Asia-Pacific populations, emphasizing cost-effectiveness and regional healthcare resources 3